NASDAQ$RCKT
Rocket Pharmaceuticals Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Rocket Pharmaceuticals reported financial and operational results for Q4 2022, highlighting positive data across clinical programs and strategic advancements.
Rocket Pharmaceuticals reported positive results across its clinical gene therapy programs and expanded its leadership in AAV cardiac gene therapy. The company's cash runway of approximately $400 million is expected to fund operations through 2024.
- Advanced pipeline demonstrated positive clinical data across four clinical gene therapy programs.
- Expanded leadership position in AAV cardiac gene therapy with opportunities for value creation.
- Established in-house cGMP manufacturing for AAV, supporting Danon pivotal trial.
- Cash, cash equivalents, and investments of approximately $400M expected to fund operations through 2024.
Headline financials
Revenue & EPS history
Rocket · Revenue · Quarterly
$0
Forward guidance
Rocket Pharmaceuticals expects its cash resources to be sufficient to fund operations through 2024, including AAV cGMP batch production and continued development of clinical programs.
Tailwinds
- Sufficient cash resources to fund operations through 2024.
- Continued development of six clinical and preclinical programs.
- Advancement of Danon Disease program towards planned pivotal trial.
- Expectations regarding safety and effectiveness of product candidates.
- Continued AAV cGMP batch production at the company’s Cranbury, N.J. R&D and manufacturing facility
Headwinds
- Impact of COVID-19 on business operations.
- Reliance on third parties for development, manufacture, and distribution.
- Outcome of litigation and competitors’ activities.
- Integration of acquired business risks.
- Unexpected expenditures
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.8%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-1.9%
Avg return
30 days after
51%
23 / 45 earnings
Positive
+18.2%
Q1 2023
Best reaction
-17.7%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.4% | -6.0% | -29.0% | |
| Q4 2025 | +10.8% | +6.4% | -16.8% | |
| Q3 2025 | +0.3% | +2.2% | +2.8% | |
| Q1 2025 | -0.6% | +0.9% | -55.7% | |
| Q4 2024 | +0.5% | -2.0% | -19.3% | |
| Q3 2024 | -0.7% | -8.8% | -21.0% | |
| Q2 2024 | -3.6% | -8.8% | -14.5% | |
| Q1 2024 | -0.5% | -3.2% | -1.6% | |
| Q4 2023 | +5.0% | +4.3% | -6.9% | |
| Q3 2023 | -2.4% | -11.6% | +23.1% | |
| Q2 2023 | -2.6% | -4.2% | -7.8% | |
| Q1 2023 | +18.2% | +16.4% | +23.0% | |
| Q4 2022 | +5.9% | +14.8% | -7.7% | |
| Q3 2022 | -6.0% | -10.8% | +9.9% | |
| Q2 2022 | +4.3% | +12.3% | +1.5% | |
| Q1 2022 | -15.2% | -17.2% | +20.4% | |
| Q4 2021 | +4.3% | -2.6% | -11.4% | |
| Q3 2021 | +10.3% | +8.0% | -30.2% | |
| Q2 2021 | -4.9% | -13.9% | -1.8% | |
| Q1 2021 | -3.9% | -6.5% | +3.6% | |
| Q4 2020 | -0.7% | -1.8% | -16.9% | |
| Q3 2020 | +5.3% | +0.2% | +9.2% | |
| Q2 2020 | +6.3% | +10.6% | -8.1% | |
| Q1 2020 | -1.5% | +12.7% | +8.5% | |
| Q4 2019 | -1.1% | -7.7% | -30.3% | |
| Q3 2019 | +10.2% | +4.0% | +50.6% | |
| Q2 2019 | +4.5% | -3.2% | +0.4% | |
| Q1 2019 | +1.6% | -8.7% | -14.6% | |
| Q4 2018 | -4.7% | -2.1% | +27.4% | |
| Q3 2018 | -1.0% | -12.5% | -17.6% | |
| Q2 2018 | +3.8% | -5.3% | +9.0% | |
| Q1 2018 | +6.5% | +19.8% | +23.2% | |
| Q4 2017 | -0.4% | +0.2% | -19.2% | |
| Q3 2017 | +2.0% | +15.7% | +3.6% | |
| Q2 2017 | +8.3% | +16.7% | +13.3% | |
| Q1 2017 | -9.6% | +0.0% | -1.4% | |
| Q4 2016 | +8.7% | -4.3% | +24.6% | |
| Q3 2016 | +4.5% | +4.5% | +1.5% | |
| Q2 2016 | +0.1% | +2.7% | +1.8% | |
| Q1 2016 | -17.7% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | -6.9% | — | — | |
| Q2 2015 | -4.1% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +7.9% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro